Credit Suisse analyst Martin Auster maintained a Hold rating on Spark Therapeutics (ONCE) today and set a price target of $44. The company’s shares opened today at $44.04, close to its 52-week low of $34.53.
According to TipRanks.com, Auster is a 3-star analyst with an average return of 1.3% and a 29.7% success rate. Auster covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings Inc, Alexion Pharmaceuticals, and Intellia Therapeutics.
Spark Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $62.18.
See today’s analyst top recommended stocks >>
Based on Spark Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $47.36 million. In comparison, last year the company had a GAAP net loss of $61.82 million.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ONCE in relation to earlier this year. Earlier this month, Jeffrey Marrazzo, the CEO of ONCE bought 6,000 shares for a total of $20,700.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases.
